New hope for rare blood cancers: international trial tests smart drug cocktails

NCT ID NCT04061421

Recruiting now Disease control Sponsor: Michael Savona Source: ClinicalTrials.gov ↗

First seen Apr 04, 2026 · Last updated May 13, 2026 · Updated 6 times

Summary

This study tests new combinations of cancer drugs for people with MDS/MPN overlap syndromes, rare blood cancers. About 94 adults will receive an oral drug (ASTX727) plus another targeted medicine to see if the combination is safe and shrinks cancer. The goal is to control the disease, not cure it, as ongoing treatment is expected.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••
Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Moffitt Cancer Center
SUSPENDED

Tampa, Florida, 33612, United States
Oregon Health Sciences University
RECRUITING

Portland, Oregon, 97239, United States

Contact Email: •••••@•••••
University of Rochester Wilmot Cancer Institute
RECRUITING

Rochester, New York, 14609, United States

Contact Email: •••••@•••••
Vanderbilt-Ingram Cancer Center
RECRUITING

Nashville, Tennessee, 37232, United States

Contact

Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.

MDS/MPN